QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Erratum All Versions of this Article: mol.106.029991v1 71/2/602    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mashiko, S. Articles by Kanatani, A. Search for Related Content PubMed PubMed Citation Articles by Mashiko, S. Articles by Kanatani, A.

A Pair-Feeding Study Reveals That a Y5 Antagonist Causes Weight Loss in Diet-Induced Obese Mice by Modulating Food Intake and Energy Expenditure

Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Tsukuba, Japan (S.M., A.I., H.I., H.S., J.I., A.G., Z.O., R.M., H.M., M.J., O.O., T.F., A.K.); Department of Metabolic Research, Merck Research Laboratories, Rahway, New Jersey (D.J.M); and Merck Research Laboratories, Boston, Massachusetts (L.H.T.V.d.P.)

Neuropeptide Y (NPY) is thought to have a significant role in the physiological control of energy homeostasis. We recently reported that an NPY Y5 antagonist inhibits body weight gain in diet-induced obese (DIO) mice, with a moderate reduction in food intake. To clarify the mechanism of the antiobesity effects of the Y5 antagonist, we conducted a pair-feeding study in DIO mice. The Y5 antagonist at 100 mg/kg produced a moderate feeding suppression leading to an 18% decrease in body weight, without altering body temperature. In contrast, the pair-fed group showed only a transient weight reduction and a reduced body temperature, thus indicating that the Y5 antagonist stimulates thermogenesis. The Y5 antagonist-treated mice showed an up-regulation of uncoupling protein mRNA in brown adipose tissue (BAT) and white adipose tissue (WAT), suggesting that both BAT and WAT contribute to energy expenditure. Thus, the Y5 antagonist induces its antiobesity effects by acting on both energy intake and expenditure.

Address correspondence to: Dr. Akio Kanatani, Tsukuba Research Institute, Banyu Pharmaceutical Co. Ltd., Okubo 3, Tsukuba 300-2611, Japan. E-mail: akio_kanatani{at}merck.com

This article has been cited by other articles:

				J. Xu, M. A. Kirigiti, M. A. Cowley, K. L. Grove, and M. S. Smith Suppression of Basal Spontaneous Gonadotropin-Releasing Hormone Neuronal Activity during Lactation: Role of Inhibitory Effects of Neuropeptide Y Endocrinology, January 1, 2009; 150(1): 333 - 340. [Abstract] [Full Text] [PDF]

				J. Dark and K. M. Pelz NPY Y1 receptor antagonist prevents NPY-induced torporlike hypothermia in cold-acclimated Siberian hamsters Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2008; 294(1): R236 - R245. [Abstract] [Full Text] [PDF]

				A. A. Ortiz, L. F. Milardo, L. B. DeCarr, T. M. Buckholz, M. R. Mays, T. H. Claus, J. N. Livingston, C. D. Mahle, and K. J. Lumb A Novel Long-Acting Selective Neuropeptide Y2 Receptor Polyethylene Glycol-Conjugated Peptide Agonist Reduces Food Intake and Body Weight and Improves Glucose Metabolism in Rodents J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 692 - 700. [Abstract] [Full Text] [PDF]

				M. M. Kamiji and A. Inui Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity Endocr. Rev., October 1, 2007; 28(6): 664 - 684. [Abstract] [Full Text] [PDF]